跳转至内容
Merck
CN

PZ0162

PD 0325901

≥98% (HPLC), MKK1 (MEK1) and MKK2 (MEK2) inhibitor, powder

别名:

N-[(2R)-2,3-二羟基丙氧基]-3,4-二氟-2-[(2-氟-4-碘苯)氨基]苯甲酰胺

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C16H14F3IN2O4
化学文摘社编号:
分子量:
482.19
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
NACRES:
NA.28
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


产品名称

PD 0325901, ≥98% (HPLC)

Quality Level

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -1.8 to -3.5°, c = 1 mg/mL in methanol

color

white to off-white

solubility

DMSO: 20 mg/mL, clear

storage temp.

2-8°C

SMILES string

FC1=C(NC2=CC=C(I)C=C2F)C(C(NOC[C@H](O)CO)=O)=CC=C1F

InChI

1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1

InChI key

SUDAHWBOROXANE-SECBINFHSA-N

Gene Information

Application

PD 0325901作为抑制剂,用于细胞外信号调节激酶(ERK)抑制试验,在引物诱导性多能干细胞、 RKO结直肠癌细胞系 和人胚胎干细胞(hESCs)中进行。

Biochem/physiol Actions

通过抑制丝裂原激活的蛋白激酶(MAPK),PD 0325901对胶质母细胞瘤 和黑色素瘤的肿瘤进展产生抑制生长和抗血管生成作用。
PD 0325901是一种有效的MKK1(MEK1)和MKK2(MEK2)抑制剂。PD 0325901对MEK1和MEK2的Ki分别为1.1和0.79nM。PD 0325901对一组27种其他激酶无活性。以25mg/kg对小鼠给药时,PD 0325901对C26肿瘤pERK的抑制率达到75%。
PD 0325901是一种有效的MKK1(MEK1)和MKK2(MEK2)抑制剂。

Features and Benefits

《受体分类和信号转导》手册的 MAPKKK 页面有该化合物的介绍。想要浏览手册的其他页面, 请单击此处


Still not finding the right product?

Explore all of our products under PD 0325901


pictograms

Skull and crossbonesHealth hazard

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Chronic 4 - STOT RE 2

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


商品

The extracellular signal regulated kinase (ERK1 and ERK2) pathways are activated by mitogens and play an important role in controlling cell growth and differentiation.

Naive pluripotent stem cells cultured in vitro using specialized media and inhibitors mimic "ground-state" cells from blastocysts.


Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations
Ciuffreda L, et al.
Neoplasia, 11(8), 720-W6-720-W6 (2009)
Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901
Shannon S, et al.
BMC Cancer, 17(1), 121-121 (2017)
Bin Zhang et al.
The Journal of clinical investigation, 126(3), 975-991 (2016-02-16)
Chronic myelogenous leukemia (CML) results from transformation of a long-term hematopoietic stem cell (LTHSC) by expression of the BCR-ABL fusion gene. However, BCR-ABL-expressing LTHSCs are heterogeneous in their capacity as leukemic stem cells (LSCs). Although discrepancies in proliferative, self-renewal, and



全球贸易项目编号

货号GTIN
PZ0162-25MG04061836687472
PZ0162-5MG04061836687489